Institution statistics

SANOFI-AVENTIS DEUTSCHLAND GMBH - Germany 

This institution has been merged with: SANOFIAVENTIS.

Ranking results:

Past rankings:
2018
Criterium:Position:
Overall Score:> 1000
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2014
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:900-1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 19
As coordinator: 0
As participant: 19
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 5.999.055 0 1
2018 0 22.949.993 0 2
2017 0 53.797.881 0 4
2016 0 27.164.781 249.216 3
2015 0 21.668.972 249.216 2
2014 0 587.134 0 1
2012 0 6.978.147 366.127 2
2010 0 11.997.333 237.849 1
2006 0 2.708.285 270.829 1
2005 0 11.998.527 285.679 1
2004 0 1.600.000 320.000 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD9
NOVO NORDISK8
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT6
ASTRAZENECA AB5
ELI LILLY AND COMPANY LIMITED5
JANSSEN PHARMACEUTICA NV5
KAROLINSKA INSTITUTE5
ACADEMISCH ZIEKENHUIS LEIDEN4
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE4
KING'S COLLEGE LONDON4
LUNDS UNIVERSITET4
NOVARTIS PHARMA4
PFIZER LIMITED4
STICHTING KATHOLIEKE UNIVERSITEIT4
TECHNISCHE UNIVERSITAET DRESDEN4
ACADEMISCH ZIEKENHUIS GRONINGEN3
BAYER AKTIENGESELLSCHAFT3
BAYER PHARMA3
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG3
JDRF INTERNATIONAL3
KATHOLIEKE UNIVERSITEIT LEUVEN3
MEDIZINISCHE UNIVERSITAET WIEN3
MEDIZINISCHE UNIVERSITAT GRAZ3
UCB BIOPHARMA3
UNIVERSITA DI PISA3
UNIVERSITE DE LAUSANNE3
UNIVERSITE LIBRE DE BRUXELLES3
UNIVERSITY OF BIRMINGHAM3
UNIVERSITY OF DUNDEE3
UNIVERSITY OF HELSINKI3
UNIVERSITY OF NEWCASTLE UPON TYNE3
UNIVERZA V LJUBLJANI3
ABBVIE INC2
ANTAROS MEDICAL AB2
BRISTOLMYERS SQUIBB COMPANY CORP2
CENTRE HOSPITALIER DE LUXEMBOURG2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE2
CHU HOPITAUX DE BORDEAUX2
EBERHARD KARLS UNIVERSITAET TUEBINGEN2
EUROPEAN MOLECULAR BIOLOGY LABORATORY2
F HOFFMANNLA ROCHE2
HANNOVERSCHE KINDERHEILANSTALT2
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE2
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER2
INSTITUT DE RECHERCHES SERVIER2
ITASUOMEN YLIOPISTO2
KUNGLIGA TEKNISKA HOEGSKOLAN2
LINKOEPING UNIVERSITY2
LIPOTYPE2
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN2
OSLO UNIVERSITETSSYKEHUS HF2
OULUN YLIOPISTO2
REGION HOVEDSTADEN2
SIB INSTITUT SUISSE DE BIOINFORMATIQUE2
SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH2
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE2
THE LEONA M AND HARRY B HELMSLEY CHARITABLE TRUST2
THE UNIVERSITY OF EXETER2
THE UNIVERSITY OF SHEFFIELD2
UNIVERCELL BIOSOLUTIONS SAS2
UNIVERSITA DEGLI STUDI DI SIENA2
UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETIPESCARA2
UNIVERSITAET BERN2
UNIVERSITAET ULM2
UNIVERSITATSKLINIKUM ERLANGEN2
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN2
UNIVERSITY OF COPENHAGEN2
UNIVERSITY OF LEEDS2
UNIVERSITY OF TURKU2
ABBVIE DEUTSCHLAND GMBH & CO KG1
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM1
ACREO AB1
ALCYOMICS1
ALLERGAN LIMITED1
ANOCCA AB1
APITOPE INTERNATIONAL NV1
ARISTOTLE UNIVERSITY OF THESSALONIKI1
ARTTIC IN BRUSSELS SPRL1
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS1
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1
ASSOCIATION LYON BIOPOLE1
ASTELLAS PHARMA EUROPE BV1
ASTRAZENECA UK LIMITED1
AVENTIS PHARMA RECHERCHEDEVELOPPEMENT1
AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO1
BAYER1
BIOASCENT DISCOVERY LIMITED1
BIOWISDOM LIMITED1
BIOXYDYN LIMITED1
BOEHRINGER INGELHEIM PHARMA GMBH & CO KG1
BRUKER BIOSPIN MRI1
BUNDESMINISTERIUM FUER BILDUNG UND FORSCHUNG1
CAPSANT NEUROTECHNOLOGIES1
CARDIFF UNIVERSITY1
CARLSBERG LABORATORY1
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE1
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE1
CEREBRICON1
CERTARA UK LIMITED1
CHALMERS TEKNISKA HOEGSKOLA AB1
Constancy:

Total number of partners:411

Partner loyalty:
Frequent Partner: (> 2 projects): 126
Rare Partner: 285

Frequent / Rare Partner Ratio: 0.44

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES6
RTD HORIZONTAL TOPICS3

Project overview:

Start dateProjectacronymrolefundingpartners
2020-05-01Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA INNODIA HARVESTparticipant5.999.05540
2018-12-01European Screening Centre; Unique Library for Attractive Biology ESCulabparticipant18.249.99320
2018-05-01Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production iConsensusparticipant4.700.00019
2017-11-01Liver Investigation: Testing Marker Utility in Steatohepatitis LITMUSparticipant15.797.88156
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-09-01Rheuma Tolerance for Cure RTCureparticipant6.000.00020
2017-01-01Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106 IB4SD-TRISTANparticipant12.000.00021
2016-09-01Biomarker Enterprise to Attack DKD - Sofia ref.: 115974 BEAt-DKDparticipant15.085.93731
2016-04-01Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881 RHAPSODYparticipant8.130.00027
2016-01-01ISOTOPIC LABELING FOR DRUG INNOVATION ISOTOPICSparticipant3.948.84413
2015-11-01Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes – Sofia ref.: 115797 INNODIAparticipant17.630.00036
2015-01-01Rapid Bioprocess Development Biorapidparticipant4.038.9729
2014-01-01Complementary Synthetic Strategies toward Heterocyclic Boronates COSSHNETparticipant587.1342
2012-11-01Coordinating Action Systems Medicine – Implementation of Systems Medicine across Europe CASYMparticipant2.996.47722
2012-01-01European Training Network for Excellence in Molecular Imaging in Diabetes BetaTrainparticipant3.981.67010
2010-11-01The European Network for Translational Research in Atrial Fibrillation EUTRAFparticipant11.997.33320
2006-01-01Chemical genomics by activity monitoring of proteases CAMPparticipant2.708.28510
2005-10-01Innovative medicines for europe INNOMEDparticipant11.998.52742
2004-05-01Heritability of chronic neuropathic pain PAINGENESparticipant1.600.0005
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum